Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia. Chronic myelogenous leukemia (CML) is a slow-growing cancer of the light-colored blood cells. It is also sometimes called chronic myeloid, chronic granulocytic or chronic myelocytic leukemia. CML is a popular leukemia. In the United States, much than 20,000 folk have CML and about 4,600 original cases are diagnosed each year. Most cases of CML happen in adults, but about 2 to 4% of CML patients are children. CML is an acquired irregularity that involves the hematopoietic stalk cubicle.

It is characterized by a cytogenetic aberration consisting of a reciprocal translocation between the long arms of chromosomes 22. The translocation results in a shortened chromosome 22, an observation first described by Nowell and Hungerford and subsequently termed the Philadelphia (Ph) chromosome after the city of discovery. Early signs and symptoms of CML are often vague. They may include fever, losing weight without trying, loss of appetite and feeling run-down or tired, pain or fullness below the ribs on the left side and sweating excessively during sleep (night sweats). Chronic myelogenous leukemia is a rare form of leukemia.

Chronic myelogenous leukemia is affecting simply one to two of every 100,000 people. Exposure to really higher levels of radioactivity increases the danger of developing chronic myelogenous leukemia the simply known danger element for this character of cancer. Survivors of a nuclear bomb attack or an atomic reactor accident are at high danger of developing chronic myelogenous leukemia. Treatment normally consists of respective chemotherapeutic agents used to interrupt the output of leukemic cells.

These treatments may be followed by stalk cubicle transplantation. A marrow or incidental blood cubicle transplantation using cells from a family member or unknown giver (an allogeneic transplantation) is the simply known treatment that can heal CML. A transplantation replaces the irregular cells in the patient’s ivory marrow with robust cells from a giver. Autologous transplantation (using the patient’s own cells) is being studied as a cure for CML that returns after Gleevec treatment. Bone marrow transplant was too used as initial treatment for CML in younger patients before the coming of imatinib.

Visit MyCMLCare.com, your comprehensive source for information and support for chronic myeloid leukemia (CML). Whether you are newly diagnosed or have been living with CML, you are not alone. In 2009, about 22,475 people in the United States were living with this disease. A cancer diagnosis can be very emotional for you and your family. But once you know more about chronic myeloid leukemia (CML), you can be an active partner in the management of your health.

MyCMLCare.com was created especially for people with CML and their caregivers. It provides a great range of topics, interactive features, and free materials to help you, your family, and friends. To build your knowledge of chronic myeloid leukemia (CML) and find the support you need, they encourage you to visit MyCMLCare.com frequently and bookmark your favorite sections.

Despite the use of today’s preventive measures, VTE still happens. It’s still the monkey on your back.

For many post–orthopedic surgical patients, venous thromboembolism (VTE) poses a significant health risk. VTE consists of 2 potentially life–threatening conditions :
- Deep vein thrombosis (DVT)
- Pulmonary embolism (PE)

These conditions can lead to long-term complications.

Learn about a treatment option for metastatic colorectal cancer and an initial treatment option for locally or regionally advanced head and neck cancer.

Colon Cancer:
ERBITUX (Cetuximab) is indicated for the treatment of patients who have colorectal cancer that has spread to other parts of the body and whose tumor expresses a protein called an Epidermal Growth Factor Receptor (EGFR).

Head & Neck Cancer:
ERBITUX (Cetuximab), in combination with radiation therapy, is indicated for the initial treatment of a certain type of locally or regionally advanced head and neck cancer.